---
type: "Symbol"
title: "InventisBio (688382.SH) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/688382.SH/topics.md"
symbol: "688382.SH"
parent: "https://longbridge.com/en/quote/688382.SH.md"
count: 6
datetime: "2026-03-13T20:25:43.581Z"
locales:
  - [en](https://longbridge.com/en/quote/688382.SH/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688382.SH/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688382.SH/topics.md)
---

# InventisBio (688382.SH) — Community Discussions

### [Losses remain, but the story isn't over: InventisBio seeks second capital pricing in the southbound market](https://longbridge.com/en/topics/37918054.md)

- Author: [港股研究社](https://longbridge.com/en/profiles/3199113.md)
- Datetime: 2026-01-19T07:30:43.000Z
- Comments: 0
- In July 2022, InventisBio was listed on the STAR Market at 18.12 yuan per share, with its first-day plunge of 23% becoming a microcosm of the bursting valuation bubble of innovative pharmaceutical com

### [Junshi Biosciences brings the first chemotherapy-free TIL therapy to the Hong Kong stock market: payment gate opens, but clinical trials are the real test](https://longbridge.com/en/topics/37093811.md)

- Author: [港股研究社](https://longbridge.com/en/profiles/3199113.md)
- Datetime: 2025-12-12T11:33:04.000Z
- Comments: 0
- As the year draws to a close, the IPO frenzy in the biopharmaceutical sector of the Hong Kong stock market remains highly volatile. According to the latest report from KPMG, it is expected that the nu

### [抢占抗痛风稀缺赛道，国内多家药企处于后期研发管线](https://longbridge.com/en/topics/11621852.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-02-18T07:13:04.000Z
- Comments: 0
- 抢占稀缺赛道，解决未被满足的市场需求，是创新药企收获高额收益的 “利润沃土”。已经长期缺乏优异疗效新药的痛风领域，可谓具备了创新的土壤，就看能否诞生新一代抗痛风药 “最强捕手”？ 一、10 年未有新药获批，抗痛风药市场潜力大痛风是一种常见且复杂的关节炎类型，患者多在夜晚发病，常会出现突发一个或多个关节重度疼痛，各个年龄段都可能患病。痛风的诱因主要是食用了富含大量嘌呤的食物...

### [这两个靶点，外资药企遇挫，国内药企生机盎然](https://longbridge.com/en/topics/10571300.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-12-16T02:23:40.000Z
- Comments: 0
- 如今创新药的战场，已经不仅仅是国内药企间的争斗，还有为了抢夺海外市场，由国内药企向外资药企发起的各个靶点的挑战。毕竟我国创新药尚处于起步阶段，仅有少数药企敢投入高成本做原始创新。因此，许多尚未成药甚至是 “不可成药” 的靶点，都由外资药企带头攻克。不过，国内药企也在"师夷长技以制夷"，先理解、学习再实现超越。KRAS、Claudin 18.2 这两个靶点...

### [近 2 亿患者，国产药企竟挖到了下一个 “金矿”](https://longbridge.com/en/topics/10463234.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-11-08T12:23:37.000Z
- Comments: 0
- 创新药研发的最大前景，就在于解决临床未被满足的需求。痛风疾病就存在巨大的未被满足的临床需求，不仅全球患者人数持续增加并趋向年轻化，而且现有治疗药物尚存不足，使得抗痛风药市场呈现出高景气度。例如，$Hengrui Pharma(600276.SH) 、一品红、$InventisBio(688382.SH) 和$Sunshine Guojian Pharmaceutical(688336.SH) 等国

### [前有百济、再鼎，后有益方生物、加科思，国内药企霸道抢食 KRAS G12C 抑制剂](https://longbridge.com/en/topics/3697585.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-11-28T14:14:15.000Z
- Comments: 0
- 让所有靶点都成药，是药品研发的愿景和使命。在 2021 年度中国生物医药融资额最高的 TOP10 靶点中，除了 JAK 家族、HER2、CD19 等大热门靶点以外，曾被称为 “不可成药” 的 KRAS 靶点也赫然在列。KRAS 是第一个被发现的人类肿瘤基因，也是 “最难攻克的靶点”，从 1982 年被发现至今的 40 年间，无数药企针对 KRAS 靶点开展的临床试验经历了一次又一次的失败。幸运的是

## References

- [InventisBio (688382.SH)](https://longbridge.com/en/quote/688382.SH.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688382.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688382.SH/topics.md)